Cancer immunotherapy. (Q39958332)

15 September 2017

1 reference

title

Cancer immunotherapy. (English)

1 reference

15 September 2017

1 reference

Constantin N Baxevanis

series ordinal

1

1 reference

PubMed ID

19650714

15 September 2017

Sonia A Perez

series ordinal

2

1 reference

PubMed ID

19650714

15 September 2017

Michael Papamichail

series ordinal

3

1 reference

15 September 2017

1 January 2009

1 reference

Critical Reviews in Clinical Laboratory Sciences

15 September 2017

1 reference

15 September 2017

46

1 reference

15 September 2017

4

1 reference

15 September 2017

167-189

1 reference

Cancer immunotherapy: the interferon-alpha experience

15 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Aptamers: an emerging class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Combined modality immunotherapy and chemotherapy: a new perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

BiTEs: bispecific antibody constructs with unique anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin-2: inception, impact, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin-7: master regulator of peripheral T-cell homeostasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Cytokines and autoimmunity: redundancy defines their complex nature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Multiple roles for CD4+ T cells in anti-tumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Differential tumor surveillance by natural killer (NK) and NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Effect of interleukin 12 on tumor induction by 3-methylcholanthrene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin 21: a cytokine/cytokine receptor system that has come of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

New aspects of NK cell subset identification and inference of NK cells' regulatory capacity by assessing functional and genomic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The biological functions of T helper 17 cell effector cytokines in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Effect of IL-21 on NK cells derived from different umbilical cord blood populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin-21 signaling: functions in cancer and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Newer monoclonal antibodies for hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Monoclonal antibody mechanisms of action in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Modulation of the immune response through 4-1BB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

A molecular perspective of CTLA-4 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Multiple costimulatory modalities enhance CTL avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Structure and expression of a cloned cDNA for human interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the ?-chain from Fc(?) RI

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The T-body approach: redirecting T cells with antibody specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Genetic approaches for antigen-selective cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Impact of chimeric immune receptor extracellular protein domains on T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Building Antibodies from their Genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Alterations in T cells of cancer-bearers: whence specificity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Aptamers in immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Developing aptamers into therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Update on immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Design and development of synthetic peptide vaccines: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Therapeutic vaccination in chronic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

21 January 2018

DC-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Vaccination for treatment and prevention of cancer in animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunotherapy: bewitched, bothered, and bewildered no more

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Next generation of immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Transient T cell depletion causes regression of melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

IDO and tolerance to tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Role of Toll-like receptors in costimulating cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle- and large-T antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Sustained response initiation is required for T cell clonal expansion but not for effector or memory development in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Design and evaluation of antigen-specific vaccination strategies against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Toll-like receptors in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunosuppression in melanoma immunotherapy: potential opportunities for intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Type 1 T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

CD1: antigen presentation and T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunoregulation of autoimmunity by natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Understanding the behavior of invariant NKT cells in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Distinct functional lineages of human V(alpha)24 natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Natural killer cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The innate immune response to tumors and its role in the induction of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Natural killer cells and dendritic cells: rendezvous in abused tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Strategies for designing and optimizing new generation vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Unravelling natural killer cell function: triggering and inhibitory human NK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Allorecognition by NK cells: nonself or no self?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

NK cells, MHC class I molecules and the missing self

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recogn

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Innate immunity against hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

NK cell receptors and their ligands in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Cellular therapy: exploiting NK cell alloreactivity in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Natural killer cells: can they be useful as adoptive immunotherapy for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

CD8+ T-Cell Tolerance can be Broken by an Adenoviral Vaccine While CD4+ T-Cell Tolerance is Broken by Additional Co-administration of a Toll-Like Receptor Ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10408360902937809

10.1080/10408360902937809

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference

PubMed ID

19650714